Hepatitis B Virus (HBV) is a major global health burden. Interferon alpha and nucleos(t)ide
analogues are currently the standard-of-care for chronic HBV infection. However, these antiviral agents
have limited efficacy and do not result in a sustained virological response in the majority of infected patients.
Virtual Screening (VS) strategies have now a strong impact on drug discovery, the strength of this
research field has been corroborated by recent contributions in the development of novel drug candidates
which are in clinical trials or which are already available in the clinics. In this context, different VS strategies
have been applied to HBV in order to discover novel inhibitors. In this review, we summarize the VS
efforts to identify and design novel HBV interventions. We believe that the combination of in silico and in
vitro tools can lead to faster validation of novel drug targets which could accelerate the HBV drug discovery
and development efforts.
Keywords: Ligand-based virtual screening, structure-based virtual screening, quantitative structure-activity relationships,
docking, Hepatitis B Virus, inhibitors, workflow.
Rights & PermissionsPrintExport